In patients with MEN1high in particular, high MEN1 expression is significantly adversely correlated with the efficacy of the Total Therapy 6 (TT6) treatment protocol consisting of induction therapy with Melphalan/Bortezomib/Thalidomide/Dexamethasone/Cisplatin/Doxorubicin/Cyclophosphamide/Etoposide (M-VTD-PACE) followed by a high-dose M-VTD-PACE-based tandem transplant [19], and in some molecular subtypes of MM [20] (Supplementary Figure S1B). Here, MEN1 is linked to Miyoshi myopathy.